+ Watch VTUS
on My Watchlist
Lack of FDA approved products. They have a lack of sales rev. Net cash in operation activity was $7,748.54 for six months ended June 30, 2013 .Funded recerch and development programs and general administration expences.Net cash used for investing was $5.166 for six months end June 30,2013. Net cash provided by financing activety was $20,754.418 for same 6 month from sales of 220,000 shares convertible preferred stock and 6,670.000 share of common stocks
This seems like a good spot to flag Ventrus ahead of topline data for the second phase III trial of VEN307 diltiazem cream for anal fissures, expected in Q1 2014. Given that the first phase III trial was positive and the therapy is already in use on a generic basis from compounding pharmacies, it seems likely that the upcoming data will be positive. The reason the company trades with an enterprise value of only 20M is that there are serious concerns regarding the commercial potential of VEN307 regardless of its efficacy vs placebo. If the stock spikes on positive data, expect a quick fade.
Currently undervalued based on large market potential of a Hemorrhoids treatment (first to market - currently no treatment available). Good cash balance, and upcoming Q2 2012 PIII pivotal clinical trial results of two drugs. Currently trading at very low volume, once interest picks up, pps will go up.
The clearance will soon come from the fed. for this the first drug of its kind. Now Dr.s can prescribe a med for this type of problem.
High Price with Low Professional Opinion
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions